Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Tamás Jordán"'
Autor:
Tamás Jordán, Orsolya Basa-Dénes, Réka Angi, János Orosz, Zsolt Ötvös, Andrea Ujhelyi, Genovéva Filipcsei, László Molnár, Tamás Solymosi, Hristos Glavinas, Dominic Capone, Nicola Whitfield, John McDermott, Litza McKenzie, Lauren Shurety, Elizabeth Manning Duus
Publikováno v:
Pharmaceutics, Vol 13, Iss 12, p 2171 (2021)
Currently approved formulations of the androgen synthesis inhibitor abiraterone acetate (AA) consist of multiple tablets administered daily in a fasted state. Removing the food effect and switching to a suspension formulation is expected to improve t
Externí odkaz:
https://doaj.org/article/757219b1771c4087aac504ec8c9247cf
Publikováno v:
Acta Pharmaceutica Hungarica. 91:181-183
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e750cdae05b5204c766e15f7b995f2d
https://doi.org/10.33892/aph.2021.91.181-183
https://doi.org/10.33892/aph.2021.91.181-183
Autor:
Réka Angi, Orsolya Basa-Dénes, Zsolt Ötvös, Tamás Solymosi, Hristos Glavinas, Ferenc Tóth, Tamás Jordán, János Orosz
Publikováno v:
Journal of Chemical & Engineering Data.
Comparative solubility tests at 296 ± 1 K and 310 ± 1 K in 11 solvents, PAMPA permeability measurements at 296 ± 1 K and 310 ± 1 K in water, FaSSIF-V2 and FeSSIF-V2 media, thermoanalytical investig...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a60d27be28f5c162479d775e028f55c4
https://doi.org/10.1021/acs.jced.8b00566
https://doi.org/10.1021/acs.jced.8b00566
Autor:
Tamás Solymosi, Stuart Mair, Tamás Jordán, Nikoletta Erdősi, Andrea Ujhelyi, Chris Roe, Orsolya Basa-Dénes, László Molnár, Balázs Kárpáti, Réka Angi, Zsolt Ötvös, John McDermott, Hristos Glavinas
Publikováno v:
AAPS PharmSciTech. 20(2)
Celecoxib (Celebrex®) is the only widely used NSAID that selectively inhibits the COX-2 isoenzyme. Celebrex® is absorbed slowly in the fasted state and food intake further delays absorption. In this work, an amorphous water dispersible granule form
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d03119032583f5fcfb2b398af8e9a9e7
https://pubmed.ncbi.nlm.nih.gov/30684094
https://pubmed.ncbi.nlm.nih.gov/30684094
Autor:
Tamás Solymosi, Orsolya Basa-Dénes, Réka Angi, Tamás Jordán, Hristos Glavinas, Andrea Ujhelyi, Gábor Heltovics, Zsolt Ötvös
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 129
Abiraterone acetate is indicated for patients with metastatic castration resistant prostate cancer. The marketed drug product (Zytiga®) exhibits very low bioavailability in the fasted state and a substantial positive food effect. We recently develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47f11d8ba568f3a02ee098225b9a5d93
https://pubmed.ncbi.nlm.nih.gov/30610953
https://pubmed.ncbi.nlm.nih.gov/30610953
Autor:
Zsolt Ötvös, Ann Church, Hristos Glavinas, Tamás Jordán, László Molnár, Tamás Solymosi, John McDermott, Stuart Mair, Genovéva Filipcsei, Vanessa Zann, Betti Ordasi, Gábor Heltovics, Réka Angi
Publikováno v:
Cancer chemotherapy and pharmacology. 80(4)
Zytiga (abiraterone acetate, AA) is known to exhibit very low bioavailability and a significant positive food effect in men. The unfavorable pharmacokinetic properties are attributed to the inadequate and variable dissolution of the compound. Using a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::774ca1f095e5574eab78587da6d9e00f
https://pubmed.ncbi.nlm.nih.gov/28776077
https://pubmed.ncbi.nlm.nih.gov/28776077
Autor:
Réka Angi, Tamás Solymosi, Soma Ránky, Zsolt Ötvös, Betti Ordasi, Tamás Jordán, László Molnár, Gábor Heltovics, Sándor Semsey, Genovéva Filipcsei, Hristos Glavinas
Publikováno v:
International journal of pharmaceutics. 532(1)
Particle size reduction of drug crystals in the presence of surfactants (often called "top-down" production methods) is a standard approach used in the pharmaceutical industry to improve bioavailability of poorly soluble drugs. Based on the mathemati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bca34ae9f3ca725dce65674fc7894c1
https://pubmed.ncbi.nlm.nih.gov/28919099
https://pubmed.ncbi.nlm.nih.gov/28919099
Autor:
Chris Roe, Litza McKenzie, Gábor Heltovics, Tamás Solymosi, Hristos Glavinas, Orsolya Basa-Dénes, Balázs Kárpáti, Réka Angi, Tamás Jordán, John McDermott
Publikováno v:
Journal of Clinical Oncology. 36:e16555-e16555
e16555Background: Rapamune (Sirolimus) exhibits low bioavailability and high variability following oral administration. Reaching the therapeutic blood concentrations in renal cancer patients was fo...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03c9b4a139d3156f3788198b723db203
https://doi.org/10.1200/jco.2018.36.15_suppl.e16555
https://doi.org/10.1200/jco.2018.36.15_suppl.e16555
Autor:
Réka Angi, Hristos Glavinas, László Molnár, Tamás Solymosi, Ann Church, Stuart Mair, Tamás Jordán, Betti Ordasi, Genovéva Filipcsei, Vanessa Zann, John McDermott, Gábor Heltovics, Zsolt Ötvös
Publikováno v:
Journal of Clinical Oncology. 36:e17036-e17036
e17036Background: Zytiga (Abiraterone acetate, AA) is known to exhibit very low bioavailability and a significant positive food effect. This is attributed to the inadequate and variable dissolution...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aac542316ec078e3da5ea748011a8a83
https://doi.org/10.1200/jco.2018.36.15_suppl.e17036
https://doi.org/10.1200/jco.2018.36.15_suppl.e17036